Linezolid optic neuropathy.
Journal
Current opinion in ophthalmology
ISSN: 1531-7021
Titre abrégé: Curr Opin Ophthalmol
Pays: United States
ID NLM: 9011108
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
medline:
28
9
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
ppublish
Résumé
In this article, we reviewed 67 reported cases of linezolid optic neuropathy and describe the common characteristics and expectations for recovery with an emphasis on recent findings in the literature. Linezolid classically causes a reversible, duration-dependent optic neuropathy. However, in our review, we found only 66.7% of patients recovered complete visual function. Vision loss most commonly affected visual acuity followed by visual field and color vision. We also found patients taking higher doses of linezolid experienced full recovery less often, suggesting a dose-dependent component of linezolid optic neuropathy. Linezolid use has increased in frequency and duration, especially in the treatment of drug-resistant tuberculosis, and data indicate that these patients experience lower rates of complete vision recovery compared with patients taking linezolid for other indications. Linezolid is an effective medication for treating drug-resistant infections; however, it may result in optic neuropathy. It is reasonable for patients on linezolid to undergo screening examinations, especially those on higher doses or for prolonged duration of therapy.
Identifiants
pubmed: 37603423
doi: 10.1097/ICU.0000000000000995
pii: 00055735-990000000-00114
doi:
Substances chimiques
Linezolid
ISQ9I6J12J
Anti-Infective Agents
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
481-486Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997; 41:2127–2131.
Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009; 59: (Suppl 1): S59–S74.
Pfizer Australia. Australian product information - Zyvox® (linezolid). Updated 22 June 2022. Available at: https://secure.healthlinks.net.au/content/pf/retriever.cfm?product=pfpzyvoa10913 . [Accessed 3 April 2023]
Brandariz-Núñez D, Hernández-Corredoira V, Guarc-Prades E, García-Navarro B. Optic neuropathy associated with linezolid: systematic review of cases. Farm Hosp 2019; 43:61–65.
Dempsey SP, Sickman A, Slagle WS. Case report: linezolid optic neuropathy and proposed evidenced-based screening recommendation. Optom Vis Sci 2018; 95:468–474.
Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367:1508–1518.
Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4:528–531.
Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 2015; 7:603–615.
Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy. Neurology 2006; 66:595–598.
Azamfirei L, Copotoiu SM, Branzaniuc K, et al. Complete blindness after optic neuropathy induced by short-term linezolid treatment in a patient suffering from muscle dystrophy. Pharmacoepidemiol Drug Saf 2007; 16:402–404.
Joshi L, Taylor SR, Large O, et al. A case of optic neuropathy after short-term linezolid use in a patient with acute lymphocytic leukemia. Clin Infect Dis 2009; 48:e73–e74.
Rasool N, Boudreault K, Lessel S, et al. Tacrolimus optic neuropathy. J Neuroophthalmol 2018; 38:160–166.
Passman RS, Bennett CL, Purpura JM, et al. Amiodarone-associated optic neuropathy: a critical review. Am J Med 2012; 125:447–453.
Sharma R, Marasini S, Sharma AK, et al. Methanol poisoning: ocular and neurological manifestations. Optom Vis Sci 2012; 89:178–182.
Saijo T, Hayashi K, Yamada H, Wakakura M. Linezolid-induced optic neuropathy. Am J Ophthalmol 2005; 139:1114–1116.
Lee S, Kang BH, Ryu WY, et al. Is severe and long-lasting linezolid-induced optic neuropathy reversible? Intern Med 2018; 57:3611–3613.
Aljebreen MA, Alotaibi AK, Alrobaian M. Linezolid-induced toxic optic neuropathy. Middle East Afr J Ophthalmol 2020; 27:235–237.
Karuppannasamy D, Raghuram A, Sundar D. Linezolid-induced optic neuropathy. Indian J Ophthalmol 2014; 62:497–500.
Grohmann SM, Berman A, Grassi MA. Linezolid-induced photoreceptor dysfunction masquerading as autoimmune retinopathy. Doc Ophthalmol 2020; 140:77–82.
Khadilkar SV, Yadav RS, Rajan S. Linezolid optic neuropathy: be careful and quick. J Assoc Physicians India 2013; 61:866–867.
Jaspard M, Butel N, Helali NE, et al. Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France. Emerg Infect Dis 2020; 26:1792–1800.
González Saldaña N, Galvis Trujillo DM, Borbolla Pertierra AM, et al. Linezolid-associated optic neuropathy in a pediatric patient with Mycobacterium nonchromogenicum. Medicine (Baltimore) 2017; 96:e9200.
Mehta S, Das M, Laxmeshwar C, et al. Linezolid-associated optic neuropathy in drug-resistant tuberculosis patients in Mumbai, India. PLoS One 2016; 11:e0162138.
World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014.
Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40:1430–1442.
Lifan Z, Sainan B, Feng S, et al. Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2019; 23:1293–1307.
Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 2016; 15:41.
Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015; 45:161–170.
Pfizer, Inc. Study to evaluate eye function in patients taking linezolid for six weeks or greater. ClinicalTrials.gov. 26 June 2015. Available at: https://clinicaltrials.gov/ct2/show/results/NCT00359632?view=results . [Accessed 9 May 2023]
Chamberlain PD, Sadaka A, Berry S, Lee AG. Ethambutol optic neuropathy. Curr Opin Ophthalmol 2017; 28:545–551.
Kho RC, Al-Obailan M, Arnold AC. Bitemporal visual field defects in ethambutol-induced optic neuropathy. J Neuroophthalmol 2011; 31:121–126.
Libershteyn Y. Ethambutol/linezolid toxic optic neuropathy. Optom Vis Sci 2016; 93:211–217.
Sadun AA, Carelli V. Mitochondrial function and dysfunction within the optic nerve. Arch Ophthalmol 2003; 121:1342–1343.
Javaheri M, Khurana RN, O’hearn TM, et al. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol 2007; 91:111–115.
Wang L, Dong J, Cull G, et al. Varicosities of intraretinal ganglion cell axons in humans and nonhuman primates. Invest Ophthalmol Vis Sci 2003; 44:2–9.
Chen JJ, McKeon A, Greenwood TM, et al. Clinical utility of antiretinal antibody testing. JAMA Ophthalmol 2021; 139:658–662.
Heidari S, Khalili H. Linezolid pharmacokinetics: a systematic review for the best clinical practice. Eur J Clin Pharmacol 2023; 79:195–206.
Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011; 66: (Suppl 4): iv7–iv15.
Han D, Wang J, Tang K, et al. Cataract with linezolid-induced toxic optic neuropathy: case report and mini review. Research Square 2023; https://doi.org/10.21203/rs.3.rs-2558359/v1
doi: 10.21203/rs.3.rs-2558359/v1
Bano S, Nawaz A, Numan A, et al. A case report and literature review of the outcome of linezolid-induced optic and peripheral neuropathy in patients with multidrug-resistant pulmonary TB. Front Neurol 2022; 13:908584.
Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 37:1389–1391.
McKinley SH, Foroozan R. Optic neuropathy associated with linezolid treatment. J Neuroophthalmol 2005; 25:18–21.
Frippiat F, Bergiers C, Michel C, et al. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 2004; 53:1114–1115.
Kulkarni K, Del Priore LV. Linezolid induced toxic optic neuropathy. Br J Ophthalmol 2005; 89:1664–1665.
Kiuchi K, Miyashiro M, Kitagawa C, Wada S. Linezolid-associated optic neuropathy in a patient with ocular sarcoidosis. Jpn J Ophthalmol 2009; 53:420–424.
Patel C, Ramchandani S. Comment on linezolid induced optic neuropathy. Indian J Ophthalmol 2015; 63:75–76.
Agrawal R, Addison P, Saihan Z, et al. Optic neuropathy secondary to linezolid for multidrug-resistant mycobacterial spinal tuberculosis. Ocul Immunol Inflamm 2015; 23:90–92.
Park DH, Park TK, Ohn YH, et al. Linezolid induced retinopathy. Doc Ophthalmol 2015; 131:237–244.
Ishii N, Kinouchi R, Inoue M, Yoshida A. Linezolid-induced optic neuropathy with a rare pathological change in the inner retina. Int Ophthalmol 2016; 36:761–766.
Han J, Lee K, Rhiu S, et al. Linezolid-associated optic neuropathy in a patient with drug-resistant tuberculosis. J Neuroophthalmol 2013; 33:316–318.
Corallo CE, Paull AE. Linezolid-induced neuropathy. Med J Aust 2002; 177:332.
Srivastava A, Kshetrimayum S, Gupta SK, Kant S. Linezolid-induced optic neuropathy in XDR pulmonary TB: a case series. Indian J Tuberc 2017; 64:129–133.
Kreps EO, Brown L, Rennie IG. Clinical recovery in linezolid-induced optic nerve toxicity. Acta Ophthalmol 2017; 95:e341–e342.
Agashe P, Doshi A. Linezolid induced optic neuropathy in a child treated for extensively drug resistant tuberculosis: a case report and review of literature. Saudi J Ophthalmol 2019; 33:188–191.
Rosenzweig SD, Yancoski J, Bernasconi A. Thirteen years of culture-positive M. bovis-BCG infection in an IL-12Rbeta1 deficient patient: treatment and outcome. J Infect 2006; 52:e69–e72.
Zivkovic SA, Lacomis D. Severe sensory neuropathy associated with long-term linezolid use. Neurology 2005; 64:926–927.
Rho JP, Sia IG, Crum BA, et al. Linezolid-associated peripheral neuropathy. Mayo Clin Proc 2004; 79:927–930.
Pilania RK, Arora A, Agarwal A, et al. Linezolid-induced mitochondrial toxicity presenting as retinal nerve fiber layer microcysts and optic and peripheral neuropathy in a patient with chronic granulomatous disease. Retin Cases Brief Rep 2021; 15:224–229.
Shah RK, Lamichhane S. Linezolid induced optic neuropathy, a serious yet reversible adverse effect: a case report. EJMCR 2017; 1:114–121.
Kardani S, Hadia R, Shah A, et al. A case report on reversible toxic optic neuropathy on long term treatment of linezolid in extensively drug-resistant tuberculosis patient. J Pharm Res Int 2021; 33:7–11.
Yoon YS, Lee CK. Optic neuropathy after taking linezolid. J Korean Ophthalmol Soc 2019; 60:1363–1368.
Bhonsale GR, Amberkar SS. Long-term linezolid: unnerving the nerves? Kerala J Ophthalmol 2021; 33:344–348.
Berkovitz L, Krasnitz I, Beiran I, et al. Isolated reversible toxic optic neuropathy secondary to linezolid. J Clin Ophthalmol Res 2017; 5:40–42.
Xerri O, Lamire B, Nasser G, et al. Severe linezolid-induced toxic optic neuropathy. J Français d’Ophtalmologie 2015; 38:e55–e58.
Rana P, Roy V, Ahmad J. Drug-induced optic neuropathy in a case of extensively drug-resistant pulmonary tuberculosis. J Basic Clin Physiol Pharmacol 2018; 30:139–140.
De Vriese AS, Van Coster R, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42:1111–1117.